Clinical Trials Browser

Phase 2 × pertuzumab × Endocrine × Clear all

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 5 charts

CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase 2 Completed

43 enrolled 9 charts

Carcinoma, Neuroendocrine